The U.S. Patent Office has accepted a patent application for the iBio Inc. iBioModulator platform. The platform aims to improve the potency and effectiveness of vaccines used to fight flu, anthrax and other diseases capable of causing epidemics.iBio Inc. is based in Newark, Del.
When issued, this patent as well as another one already approved would offfer broad coverage for the iBioModulator platform, according to the company.
“The iBioModulator platform is separate and independent from our plant-based biologics technology,” said Robert B. Kay, iBio’s chairman and CEO. “Although we recommend its use together with our iBioLaunch platform to achieve maximum efficiency in producing the fused protein, the iBioModulator is usable independently and is applicable to recombinant vaccines made with any system. We expect strong interest in its use by both corporate and government clients.”
The iBioLaunch platform uses plants, grown with the help of robotics, to make vaccines.
“This patent will provide further opportunities for commercial development of our iBioModulator platform for subunit vaccine products,” said Robert Erwin, iBio’s president. “Application of this technology to anthrax is timely because of the threat posed by anthrax due to its potential use in bioterrorism and recent outbreaks among wildlife in the United States. There is a clear need for an improved vaccine for anthrax and for improved production methods that allow for safe, mass-production at a reasonable cost.”
